Sam Brusco, Associate Editor12.06.22
French-American pioneer in accessible surgical innovation Moon Surgical has obtained U.S. Food and Drug Administration (FDA) clearance for its Maestro surgical robotics system.
Maestro aims to support the 18.8 million annual soft tissue surgical procedures not currently supported by telerobotic systems on the market. The robot is small, adaptable, and can be integrated into existing workflows, according to the company.
The system’s capabilities can bolster operating room efficiency and permit alternative labor models.
"We have seen tremendous interest from surgical practices in the U.S. and are eager to see surgeons and their staff using Maestro for the benefit of their patients in that geography," Professor Brice Gayet, a visionary laparoscopist and co-founder of Moon Surgical, told the press. "Maestro will dramatically change the way in which the standard of care is performed in soft tissue surgery, for millions of patients each year."
Moon System at this moment is finalizing development of its first commercial system.
Maestro aims to support the 18.8 million annual soft tissue surgical procedures not currently supported by telerobotic systems on the market. The robot is small, adaptable, and can be integrated into existing workflows, according to the company.
The system’s capabilities can bolster operating room efficiency and permit alternative labor models.
"We have seen tremendous interest from surgical practices in the U.S. and are eager to see surgeons and their staff using Maestro for the benefit of their patients in that geography," Professor Brice Gayet, a visionary laparoscopist and co-founder of Moon Surgical, told the press. "Maestro will dramatically change the way in which the standard of care is performed in soft tissue surgery, for millions of patients each year."
Moon System at this moment is finalizing development of its first commercial system.